Dr. Lyke is a clinical translational investigator with recognized expertise in malaria, tropical diseases, and parasite immunology. She completed her residency work at Duke University followed by an Infectious Diseases Fellowship at The Johns Hopkins School of Medicine. She is board certified in Infectious Diseases and maintains an HIV clinic in addition to attending on the hospital wards as an Infectious Diseases Attending. In addition to field work in Mali, West Africa, she has rebuilt the malaria challenge capabilities at UMB. This capacity has led to novel vaccine work including leading the first-in-humans challenge trial of a whole-organism Pf sporozoite malaria vaccine and the first-in-humans aseptic malaria challenge. She has planned and led studies aimed at developing parenterally-administered malaria challenges and continue to advance the whole organism, Pf sporozoite malaria vaccine approach.
In addition to clinical vaccine and challenge studies, Dr. Lyke is the Head of the Immunoparasitology Unit and studies the human immune response to parasites. She plans and participates in field, clinical and immunologic studies of Plasmodium falciparum and helminths. Immunologic studies involve the investigation of different components of the human immune response, including immunomodulation via T and B regulatory cells, cell multifunctionality, T and B cell memory, mechanisms of lymphocyte activation, cytotoxic T cell activity and lymphoid cell populations involved in the generation of protective immune responses. In collaboration with colleagues at the University of Bamako in Mali, Dr. Lyke has aided in the development of a field research site in the Dogon country of Mali. This field station has been the site of studies of drug resistance and pathogenesis of severe malaria, and has completed several malaria vaccine trials.
- Malaria Vaccine Development
- Parasite Immunology
- Co-parasite Infection
- Infectious Diseases
- Geographic Medicine
Lyke KE, Wang A, Dabo A, Arama C, Daou M, Diarra I, Plowe CV, Doumbo OK, Sztein MB. Antigen-Specific B Memory Cell Responses to Plasmodium falciparum Malaria Antigens and Schistosoma haematobium Antigens in Co-infected Malian Children. PloS ONE, 2012; e37868. doi:10.1371/journal.pone.0037868. PMC3367916.
Lyke KE*,Epstein JE*, Tewari K* (*Co-first authors), Sim BKL, Billingsley PF, Laurens MB,6, Gunasekera A,Chakravarty S, James ER, Sedegah M, Richman A, Velmurugan S, Reyes S, Li M, Tucker K,Ahumada A, Ruben A, Li T, Stafford R, Eappen AG, Tamminga C, Bennett JW, Ockenhouse CF, Murphy JR, Komisar J, Thomas N, Loyevsky M, Birkett A, Plowe CV, Loucq C, Edelman R, Richie TL, Seder RA** , Hoffman SL** (* Co-first authors, ** Co-last authors) The Attenuated Sporozoite Vaccine Laboratory and Clinical Development Teams, Live Attenuated Malaria Vaccine Designed to Protect through Hepatic CD8+ T Cell Immunity. (Online publication Sept. 8, 2011 ScienceExpress. / 8 September 2011 / Page 1 / 10.1126/science.1211548), Science, 2011 334: 475.
Thera MA, Doumbo OK, Coulibaly D, Laurens MB, Ouattara A, Kone AK, Guindo AB, Traore K, Traore I, Kouriba B, Diallo DA, Diarra I, Daou M, Dolo A, Tolo Y, Sissoko MS, Niangaly A, Sissoko M, Takala-Harrison SL, Lyke KE, Wu Y, Blackwelder W, Godeaux O, Vekemans J, Dubois MC, Ballou W, Cohen J, Thompson D, Dube T, Soisson L, Diggs CL, House B, Lanar DE, Dutta S, Heppner DG, Plowe CV. A Field Trial to Assess the Safety and Efficacy of a Blood-stage Malaria Vaccine, N Eng J Med. 2011 365: 1004-1013.
Lyke KE, Dabo A, Arama C, Daou M, Diarra I, Wang A, Plowe CV, Doumbo OK, Sztein MB. Effects of concomitant Schistosoma haematobium infection on the T regulatory cell response elicited by acute Plasmodium falciparum malaria infection in Malian children. PLoS One, 2012; 7(2):e31647. PMC3279404
Lyke KE, Fernandez-Vina MA, Cao K, Hollenbach J, Coulibaly D, Kone AK, Ando Guindo5, Burdett LA, Hartzman RJ, Wahl AR, Hildebrand WH, Doumbo OK, Plowe CV, and Sztein MB. Association of HLA Alleles with Plasmodium falciparum Severity in Malian Children. Tissue Antigens, 2011 77(6):562-571.
Lyke KE, Laurens M, Adams M, Billingsley P, Richman A, Loyevsky M, Chakravarty S, Plowe CV, Sim KL, Edelman RE, Hoffman S. Plasmodium falciparum Malaria Challenge by the Bite of Aseptic Anopheles stephensi Mosquitoes: Results of a Randomized Infectivity Trial. PLoS ONE 2010.
Lyke KE, Daou M, Diarra I, Kone AK, Thera MA, Heppner G,. Leach A, Doumbo OK, Plowe, CV and Sztein MB. Cell Mediated Immunity Elicited by the Blood Stage Malaria Vaccine Apical Membrane Antigen 1 in Malian Adults: Results of a Phase I Randomized Trial. Vaccine 2009 Mar 26;27(15):2171-6.
Lyke KE, Dabo A, Sangara L, Arama C, Daou M, Diarra I, Plowe CV, Doumbo OK, Sztein MB. Effects of concomitant Schistosoma haematobium infection on the serum cytokine levels elicited by acute Plasmodium falciparum malaria infection in Malian children. Infection and Immunity, 2006; Oct;74(10):5718-24.
Lyke K.E., Dicko A., Kone A., Coulibaly D., Guindo A., Traore K., Dra M., Diarra I., Dabo A., Sztein MB., Plowe C.V., and Doumbo OK. Association of Schistosoma haematobium infection with protection against acute Plasmodium falciparum malaria in Malian children. Am J Trop Med Hyg. 2005; Dec;73(6):1124-1130.
Lyke KE, Burges R, Cissoko, Y, Sangare L, Kone A, Fernandez-Vina M, Plowe C, Doumbo O, and Sztein MB. Interferon-gamma (IFN-gamma) production and proliferation of HLA-A*2 restricted peripheral blood mononuclear cells (PBMC) derived from Malian children with severe or uncomplicated P. falciparum malaria and healthy controls. Infect Immun. 2005; Sep;73(9):5799-808.
Lyke KE, Burges R, Cissoko Y, Sangare L, Dao M, Diarra I , Kone A, Harley R, Plowe CV, Doumbo OK and Sztein MB. Serum levels of pro-inflammatory cytokines interleukin-1 beta, IL-6, IL-8, IL-10, Tumor necrosis factor-alpha and IL-12p70 in Malian children with severe Plasmodium falciparum malaria and uncomplicated malaria or healthy controls. Infection and Immunity 2004; 72:5630-37.
Lyke, KE, Dicko A, Kone A, Coulibaly D, Guindo A, Cissoko Y, Traore, Plowe CV, and Doumbo OK. Incidence of severe Plasmodium falciparum malaria as a primary endpoint for vaccine efficacy trials in Bandiagara, Mali. Vaccine 2004; 22: 3169-3174.
Lyke KE, Diallo DA, Dicko A, Kone AK, Coulibaly D, Guindo A, Cissoko Y, Sangare L, Coulibaly S, Dakouo B, Taylor TE, Doumbo OK, and Plowe CV. Association of intraleukocytic Plasmodium falciparum malaria pigment with disease severity, clinical manifestations and prognosis in severe malaria, Am J Trop Med Hyg, 2003; 69(3):253-59.